Cenobamate
Total Payments
$3.9M
Transactions
2,709
Doctors
595
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3.9M | 2,709 | 595 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 747 | 66.1% |
| Honoraria | $957,125 | 474 | 24.8% |
| Consulting Fee | $213,886 | 86 | 5.5% |
| Food and Beverage | $58,018 | 941 | 1.5% |
| Travel and Lodging | $54,352 | 163 | 1.4% |
| Education | $22,313 | 298 | 0.6% |
Payments by Type
Research
$2.5M
747 transactions
General
$1.3M
1,962 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 59566 | SK Life Science, Inc. | $671,464 | 0 |
| An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures | SK Life Science, Inc. | $345,701 | 0 |
| YKP3089C025 | SK Life Science, Inc. | $314,830 | 0 |
| 1-FA7759 | SK Life Science, Inc. | $297,220 | 0 |
| 059566 | SK Life Science, Inc. | $243,926 | 0 |
| YKP3089C033 | SK Life Science, Inc. | $222,392 | 0 |
| 45569 | SK Life Science, Inc. | $163,237 | 0 |
| YKP3089C013 | SK Life Science, Inc. | $119,269 | 0 |
| 045569 | SK Life Science, Inc. | $78,147 | 0 |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension | SK Life Science, Inc. | $71,812 | 0 |
| 1-Q3RAS | SK Life Science, Inc. | $13,379 | 0 |
| HEOR Consultants | SK Life Science, Inc. | $4,800 | 2 |
| C025 Ph3 - PGTC (DBL)-CL-325 | SK Life Science, Inc. | $2,000 | 1 |
Top Doctors Receiving Payments for Cenobamate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $2.6M | 749 |
| , MD | Neurology | Cleveland, OH | $67,982 | 62 |
| , MD | Neurology | Bethesda, MD | $45,723 | 41 |
| , MD | Neurology | Tampa, FL | $39,353 | 48 |
| , MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $36,548 | 27 |
| , M.D | Neurology | Tulsa, OK | $36,240 | 48 |
| , M.D | Neurology | Atlanta, GA | $29,403 | 34 |
| , MD | Neurology | Salt Lake City, UT | $25,322 | 22 |
| , M.D | Neurology | Mobile, AL | $25,273 | 20 |
| , MD | Neurology | Houston, TX | $24,836 | 27 |
| , MD | Epilepsy | Cincinnati, OH | $23,608 | 27 |
| , MD | Clinical Neurophysiology | Covington, LA | $22,618 | 14 |
| , M.D | Clinical Neurophysiology | Wayne, MI | $22,589 | 13 |
| , MD | Epilepsy | Charlotte, NC | $22,006 | 29 |
| , MD | Neurology | Pittsburgh, PA | $21,631 | 20 |
| , MD | Epilepsy | New Orleans, LA | $21,580 | 18 |
| , DO | Vascular Neurology | Ocala, FL | $21,421 | 21 |
| , MD | Neurology | Chicago, IL | $20,881 | 22 |
| , M.D | Specialist | Brooklyn, NY | $20,683 | 19 |
| , D.O | Neurology | Statesville, NC | $19,266 | 26 |
| , MD | Epilepsy | Grand Rapids, MI | $18,834 | 27 |
| , M.D | Neurology | Phoenix, AZ | $17,544 | 23 |
| , M.D | Neurology | Oklahoma City, OK | $17,536 | 20 |
| , DO | Neurology | Encinitas, CA | $17,385 | 19 |
| , M.D | Neurology | Cincinnati, OH | $16,789 | 11 |
Ad
Manufacturing Companies
- SK Life Science, Inc. $3.9M
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 595
- Transactions 2,709
About Cenobamate
Cenobamate is a drug associated with $3.9M in payments to 595 healthcare providers, recorded across 2,709 transactions in the CMS Open Payments database. The primary manufacturer is SK Life Science, Inc..
Payment data is available from 2020 to 2020. In 2020, $3.9M was paid across 2,709 transactions to 595 doctors.
The most common payment nature for Cenobamate is "Unspecified" ($2.5M, 66.1% of total).
Cenobamate is associated with 13 research studies, including "59566" ($671,464).